FMW0 Stock Chart & Stats
€3.44
€0.00(0.00%)
At close: 4:00 PM EDT
€3.44
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.30 - €3.44
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€34.09M
Enterprise Value€49.04M
Total Cash (Recent Filing)€23.88M
Total Debt (Recent Filing)€2.68M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Nov 26, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,050,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.98Price Target Upside626.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressFull enrollment establishes a defined development path for enobosarm and moves the program toward clinically meaningful readouts. The planned interim and final analyses create identifiable milestones that can clarify efficacy, safety, and commercial potential over the next several quarters.
Intellectual PropertyLong-duration U.S. patent protection could support an extended commercialization window if enobosarm demonstrates clinical benefit. The claims cover combination use with weight-loss drugs and several functional outcomes, strengthening potential differentiation and future exclusivity.
Strategic Oncology FocusRefocusing sabizabulin on a defined oncology opportunity concentrates resources on a potentially high-unmet-need setting and aligns development with preclinical resistance data. Maintaining a separate obesity program also preserves multiple clinical avenues rather than relying on one asset.
Bears Say
Absent Recent RevenueZero recent revenue indicates that marketed products and development assets are not currently generating a dependable commercial base. Continued net losses weaken earnings quality and leave future financial performance dependent on successful clinical development, partnering, or a return to product sales.
Cash Burn And Financing DependencePersistent operating cash burn requires Veru to fund development through existing liquidity, asset proceeds, or external financing. Although burn has improved from earlier periods, continued negative free cash flow can dilute shareholders or constrain the pace and scope of clinical investment.
GLP-1 Competitive PressureEstablished GLP-1 products set strong efficacy expectations and have substantial market presence, raising the standard enobosarm must meet. Unless Veru proves a compelling muscle-preservation or functional benefit alongside weight loss, adoption and partnering prospects may remain difficult.
Veru News
FMW0 FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was €3.30 and its highest was €3.44 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is €34.09M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Nov 26, 2026 which is in 33 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Aug 10, 2026. The company reported -€0.268 earnings per share for the quarter, beating the consensus estimate of -€0.286 by €0.018.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru does not currently pay dividends.
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.23.
How many shares outstanding does Veru have?
Veru has 17,050,320 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -€0.268 in its last earnings report, beating expectations of -€0.286. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in DE:FMW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€24.98 (626.08% Upside)
€24.98 (626.08% Upside)
Insider Transactions
Bought Shares
Worth €4.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.78%
12-Months-Change
Fundamentals
Return on Equity
-45.89%
Trailing 12-Months
Asset Growth
35.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veru
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
FMW0 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple meaningful positive developments: full enrollment of the Phase IIb PLATEAU study with an upcoming interim analysis, demonstration of muscle-preserving benefits in the prior QUALITY study, a strategic Novo Nordisk supply agreement, a notice of allowance for a key U.S. method-of-use patent (extending protection into the 2040s), improved cash and working capital driven by a financing and realizations, and year-to-date reductions in net loss and operating cash burn. Offsetting these positives are continued net losses, ongoing negative operating cash flow, a near-term increase in R&D spend tied to PLATEAU, strong competitive pressures from established GLP-1 players, and some commercial constraint from Novo's right of first negotiation. On balance, the company showed clear progress on clinical, IP and financing fronts sufficient to fund near-term milestones, but it continues to face execution, clinical and competitive risks.View all DE:FMW0 earnings summariesFMW0 Stock 12 Month Forecast
Average Price Target
€24.98
▲(626.08% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―